🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Remedy Entertainment Oyj (HEL:REMEDY)
Finland flag Finland · Delayed Price · Currency is EUR
15.04
+0.30 (2.04%)
Nov 18, 2026, 6:29 PM EET

Remedy Entertainment Oyj Statistics

Total Valuation

HEL:REMEDY has a market cap or net worth of EUR 204.40 million. The enterprise value is 197.87 million.

Market Cap204.40M
Enterprise Value 197.87M

Important Dates

The last earnings date was Tuesday, November 3, 2026.

Earnings Date Nov 3, 2026
Ex-Dividend Date n/a

Share Statistics

HEL:REMEDY has 13.59 million shares outstanding. The number of shares has decreased by -0.04% in one year.

Current Share Class 13.59M
Shares Outstanding 13.59M
Shares Change (YoY) -0.04%
Shares Change (QoQ) +0.61%
Owned by Insiders (%) 27.65%
Owned by Institutions (%) 18.77%
Float 9.83M

Valuation Ratios

PE Ratio n/a
Forward PE 35.20
PS Ratio 2.48
PB Ratio 3.60
P/TBV Ratio 4.06
P/FCF Ratio n/a
P/OCF Ratio 47.25
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.40
EV / EBITDA 10.88
EV / EBIT 14.42
EV / FCF n/a

Financial Position

The company has a current ratio of 2.10, with a Debt / Equity ratio of 0.32.

Current Ratio 2.10
Quick Ratio 2.10
Debt / Equity 0.32
Debt / EBITDA 1.00
Debt / FCF n/a
Interest Coverage 8.75

Financial Efficiency

Return on equity (ROE) is -4.42% and return on invested capital (ROIC) is 29.00%.

Return on Equity (ROE) -4.42%
Return on Assets (ROA) 8.99%
Return on Invested Capital (ROIC) 29.00%
Return on Capital Employed (ROCE) 18.37%
Weighted Average Cost of Capital (WACC) 9.97%
Revenue Per Employee 211,571
Profits Per Employee -6,526
Employee Count378
Asset Turnover 0.86
Inventory Turnover n/a

Taxes

Income Tax -275,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +10.08% in the last 52 weeks. The beta is 1.09, so HEL:REMEDY's price volatility has been similar to the market average.

Beta (5Y) 1.09
52-Week Price Change +10.08%
50-Day Moving Average 17.30
200-Day Moving Average 15.15
Relative Strength Index (RSI) 30.92
Average Volume (20 Days) 14,978

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, HEL:REMEDY had revenue of EUR 79.97 million and -2.47 million in losses. Loss per share was -0.18.

Revenue79.97M
Gross Profit 72.66M
Operating Income 13.31M
Pretax Income -2.74M
Net Income -2.47M
EBITDA 16.30M
EBIT 13.31M
Loss Per Share -0.18
Full Income Statement

Balance Sheet

The company has 24.12 million in cash and 17.59 million in debt, with a net cash position of 6.54 million or 0.48 per share.

Cash & Cash Equivalents 24.12M
Total Debt 17.59M
Net Cash 6.54M
Net Cash Per Share 0.48
Equity (Book Value) 55.15M
Book Value Per Share 4.06
Working Capital 27.09M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.20 million and capital expenditures -4.45 million, giving a free cash flow of -250,000.

Operating Cash Flow 4.20M
Capital Expenditures -4.45M
Depreciation & Amortization 2.99M
Net Borrowing -1.44M
Free Cash Flow -250,000
FCF Per Share -0.02
Full Cash Flow Statement

Margins

Gross margin is 90.85%, with operating and profit margins of 16.64% and -3.08%.

Gross Margin 90.85%
Operating Margin 16.64%
Pretax Margin -3.43%
Profit Margin -3.08%
EBITDA Margin 20.38%
EBIT Margin 16.64%
FCF Margin n/a

Dividends & Yields

HEL:REMEDY does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield 0.04%
Shareholder Yield 0.04%
Earnings Yield -1.21%
FCF Yield -0.13%
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Analyst Forecast

The average price target for HEL:REMEDY is 21.00, which is 39.63% higher than the current price. The consensus rating is "Buy".

Price Target 21.00
Price Target Difference 39.63%
Analyst Consensus Buy
Analyst Count 2
Revenue Growth Forecast (3Y) 24.86%
EPS Growth Forecast (3Y) n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

HEL:REMEDY has an Altman Z-Score of 4.41 and a Piotroski F-Score of 4.

Altman Z-Score 4.41
Piotroski F-Score 4